Abstract：
OBJECTIVE: To present the characteristics of drug hypersensitivity reactions (DHRs) among taxane recipients with non-small cell lung carcinoma (NSCLC), and to describe the results of rapid drug desensitization (RDD).
METHODS: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards.
RESULTS: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male.
CONCLUSIONS: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients.
METHODS: A retrospective cross-sectional study included 45 patients who were treated with taxane for NSCLC and were found to be hypersensitive to taxane. All patients were administered the standard 3-bag, 12-step RDD protocol following the development of DHR. RDD success was evaluated separately for each cycle, and successful RDD was defined as the completion of the cycle with application of 12 steps of the desensitization protocol and the absence of early and/or late reactions afterwards.
RESULTS: Among 45 patients hypersensitive to taxane 43 (95.6%) successfully received taxane cycles with desensitization. Failed RDD occurred in only 2 (4.4%) patients. The total number of desensitization cycles was 183, of which 181 (98.9%) were successful. The mean age of patients with successful desensitization was 59.42 ± 10.48 years and 37 (86.0%) of them were male.
CONCLUSIONS: RDD is a reliable procedure that enables effective administration and completion of first-line taxane treatments in taxane-sensitive patients.
摘要：
目的：介绍非小细胞肺癌（NSCLC）紫杉烷患者药物超敏反应（DHRs）的特点，并描述快速药物脱敏(RDD)的结果。
方法：一项回顾性横断面研究包括45例接受紫杉烷治疗的NSCLC患者，发现对紫杉烷过敏。所有患者均给予标准的3袋，DHR开发后的12步RDD协议。RDD成功分别评估每个周期，成功的RDD定义为应用12个步骤的脱敏方案完成循环,之后没有早期和/或晚期反应.
结果：在45例紫杉烷过敏患者中，43例（95.6％）成功接受了紫杉烷循环脱敏。失败的RDD仅发生在2例（4.4％）患者中。脱敏周期总数为183个，其中181个（98.9%）成功。成功脱敏患者的平均年龄为59.42±10.48岁，其中男性37例（86.0％）。
结论：RDD是一种可靠的方法，能够在紫杉烷敏感患者中有效地给予并完成一线紫杉烷治疗。
方法：一项回顾性横断面研究包括45例接受紫杉烷治疗的NSCLC患者，发现对紫杉烷过敏。所有患者均给予标准的3袋，DHR开发后的12步RDD协议。RDD成功分别评估每个周期，成功的RDD定义为应用12个步骤的脱敏方案完成循环,之后没有早期和/或晚期反应.
结果：在45例紫杉烷过敏患者中，43例（95.6％）成功接受了紫杉烷循环脱敏。失败的RDD仅发生在2例（4.4％）患者中。脱敏周期总数为183个，其中181个（98.9%）成功。成功脱敏患者的平均年龄为59.42±10.48岁，其中男性37例（86.0％）。
结论：RDD是一种可靠的方法，能够在紫杉烷敏感患者中有效地给予并完成一线紫杉烷治疗。
